Aria Vaishnavi, Ph.D., is a cancer biologist that specializes in signal transduction, targeted therapeutics, and mouse models of human cancer. Dr. Vaishnavi obtained her B.S. degree in Biochemistry and Molecular Biology from the Honor's College at Washington State University in 2007. She completed her doctoral studies in cancer biology at the University of Colorado Denver Anschutz under the mentorship of Dr. Robert Doebele. Dr. Vaishnavi completed her postdoctoral training with Dr. Martin McMahon at the University of Utah.

Dr. Vaishnavi was recruited to The University of Texas MD Anderson Cancer Center in 2022 as an assistant professor in the Department of Cancer Biology with the support of a CPRIT Recruitment of First-Time, Tenure-Track Faculty Members award. 

Read More

Aria Vaishnavi, Ph.D., is a cancer biologist that specializes in signal transduction, targeted therapeutics, and mouse models of human cancer. Dr. Vaishnavi obtained her B.S. degree in Biochemistry and Molecular Biology from the Honor's College at Washington State University in 2007. She completed her doctoral studies in cancer biology at the University of Colorado Denver Anschutz under the mentorship of Dr. Robert Doebele. Dr. Vaishnavi completed her postdoctoral training with Dr. Martin McMahon at the University of Utah.

Dr. Vaishnavi was recruited to The University of Texas MD Anderson Cancer Center in 2022 as an assistant professor in the Department of Cancer Biology with the support of a CPRIT Recruitment of First-Time, Tenure-Track Faculty Members award.  The Vaishnavi lab's broad interests primarily focus on understanding the molecular mechanisms that drive tumor initiation, maintenance, and progression of adenocarcinomas of the lung, as well as other GI-related tumors. An overarching theme in the lab is to understand the different ways that normal signaling pathways can support and modify dominant oncogenic signaling programs, as well as minimal residual disease from different targeted therapeutic intervention strategies. Additionally, the lab is investigating the underlying cellular, molecular, and genetic mechanisms that drive lung cancer in never-smokers (LCINS).

Read Less